REG - Diaceutics PLC - Board Changes

DiaceuticsAnnouncement

01/10/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241001:nRSA3419Ga&default-theme=true

RNS Number : 3419G  Diaceutics PLC  01 October 2024

Diaceutics PLC - Board Changes

Cheryl MacDiarmid joining as a Non-Executive Director

Graham Paterson becoming Senior Independent Director

Jordan Clark joining as an Executive Director

Mike Wort resigning as a Non-Executive Director

Belfast and London, 1 October 2024 - Diaceutics PLC
(https://www.diaceutics.com/) (AIM: DXRX), a leading technology and solutions
provider to the pharma and biotech industry, today announces the following
changes to its board of directors ("Board").

 

Jordan Clark (Chief Data Officer of Diaceutics) will join the Board as an
Executive Director effective 1 October 2024. Cheryl MacDiarmid will join the
Board as a Non-Executive Director subject to the completion of usual Nominated
Adviser due diligence checks and a further announcement will be made in due
course. Having been on the Board since March 2019, Mike Wort is stepping down
as a Non-Executive Director effective 1 October 2024. Graham Paterson who is
currently a Non-Executive Director of Diaceutics will assume the role of
Senior Independent Director effective 1 October, 2024.

 

In addition, further to the 23 July 2024 announcement, Diaceutics confirms
that Deborah Davis has stepped down from the Board with effect from 1 October
2024 and Peter Keeling has succeeded Deborah as Non-Executive Chair.

 

Cheryl MacDiarmid has over 30 years' experience in the global pharmaceutical
sector, notably with GSK, ViiV Healthcare and currently as a Non-Executive
Director of AIM-listed Allergy Therapeutics. Cheryl is an internationally
recognised opinion leader in the development & commercialisation of
medicines. Trained as a pharmacist, she has held numerous senior leadership
positions in the UK, EU, US and Canada, with responsibilities including global
commercial strategy, P&L, sales, marketing, operations and Board
membership. Cheryl is passionate about bringing new therapies to the right
patients who can benefit.

 

Jordan Clark is Chief Data Officer at Diaceutics. Jordan spearheads
Diaceutics' comprehensive data strategy, spanning acquisition engineering and
data science, to deliver cutting-edge analytics to our clients and
laboratories. With over a decade of experience at Diaceutics, he has
cultivated a profound understanding of the critical role real-world data plays
in optimising precision medicine. Jordan's academic and professional
credentials in biomedical and clinical sciences, coupled with his state
licensure as a haematology scientist, underscore his expertise. Additionally,
Jordan is renowned for proficiency testing, bioinformatics and biomarker
testing, honed through his involvement with UK NEQAS.

 

Peter Keeling, Non-Executive Chair of Diaceutics commented: "I would like to
thank Mike for his valuable counsel around the IPO process and his useful
insights and support to expanding our UK data assets. We will miss him and
wish him well in his future endeavours.

 

I am delighted to warmly welcome Cheryl and Jordan to the Board of Diaceutics.
They both bring a significant depth of talent and vast experience as leaders
in their field to Diaceutics and I know their insights will play a significant
part in helping drive our continued performance and growth in the years
ahead."

 

The following information is disclosed in accordance with Schedule 2(g) of the
AIM Rules for Companies:

 

Additional information with regard to Jordan Clark:

Jordan Russell Clark, age 40, is currently or has been a director of the
following companies within the past five years:

 

 Current Directorships           Former Directorships
 J&L Clark Holdings Limited      Aptamer Group Limited (now known as  Aptamer Group plc)

 

 

Additional information with regard to Cheryl MacDiarmid:

The Company will make a further RNS announcement in due course detailing the
disclosures required under Schedule 2(g) of the AIM Rules for Companies.

 

 Enquiries:

 Diaceutics PLC
 Ryan Keeling, Chief Executive Officer           Tel: +44 (0)28 9040 6500

 Nick Roberts, Chief Financial Officer           investorrelations@diaceutics.com (mailto:investorrelations@diaceutics.com)

 Canaccord Genuity Limited (Nomad & Broker)      Tel: +44 (0)20 7523 8000
 Simon Bridges, Andrew Potts, Harry Rees

 Alma Strategic Communications                   Tel: +44(0)20 3405 0205
 Caroline Forde, Kinvara Verdon                  diaceutics@almastrategic.com

 

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to
receive the right test and the right therapy to positively impact their
disease outcome. We provide the world's leading pharma and biotech companies
with an end-to-end commercialisation solution for precision medicines through
data analytics, scientific and advisory services enabled by our platform DXRX
- The Diagnostics Network ®.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAZZGFLRGLGDZM